SiteOne Therapeutics Appoints Scott Braunstein, MD to Board of Directors
BOZEMAN, Mont., Sept. 11, 2018
BOZEMAN, Mont., Sept. 11, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced that Scott Braunstein, MD has been appointed to the Company's Board of Directors. Dr. Braunstein brings extensive leadership in sales, marketing and operations to SiteOne, as well as a successful track record of investing in biotech and pharmaceutical companies.
"We are very pleased to have Scott join our board of directors at such a pivotal time for SiteOne" said Stan Abel CEO of SiteOne Therapeutics. "Scott brings a wealth of experience in advancing and commercializing pain therapeutics. His experience in will be invaluable to our team as we continue to build SiteOne into a leading developer of non-opioid pain medicines."
Dr. Braunstein most recently served as the Chief Operating Officer at Pacira Pharmaceuticals. In this role Dr. Braunstein was responsible for overseeing sales, marketing, strategy and business development, playing an integral part in global licensing including securing a partnership with Johnson and Johnson in the United States for the Company's lead drug EXPAREL. During his time at Pacira, his roles included Chief Operating Officer, Chief Strategy Officer and SVP of Corporate Strategy and Development.
"I am honored to be appointed to the board of SiteOne Therapeutics and I look forward to working with my fellow board members and SiteOne's management team to help them accomplish their goal of developing a new class of effective non-opioid pain treatments" said Scott Braunstein.
Prior to Dr. Braunstein's role at Pacira, he served as a health care portfolio manager at Everpoint Asset Management. From 2002 through 2014 Dr. Braunstein was a healthcare analyst and managing director at J.P. Morgan Asset Management. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group while also serving as assistant clinical professor at the Albert Einstein College of Medicine and for Columbia University Medical Center. Dr. Braunstein currently serves on the Board of Directors of ArTara Therapeutics and Esperion Pharmaceuticals and is an operating partner at Aisling Capital. Dr. Braunstein holds a bachelor's degree in business from Cornell University and earned his medical degree from the Albert Einstein College of Medicine.
About SiteOne Therapeutics, Inc.
SiteOne Therapeutics is a biopharmaceutical company headquartered in Bozeman, Montana with a research laboratory in South San Francisco, California. Since its inception, SiteOne has been dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company's therapeutic candidates are highly selective sodium ion channel 1.7 (Nav1.7) inhibitors based on naturally occurring small molecules. Given the urgent need for new, non-opioid solutions for managing pain, SiteOne is focused on advancing its lead product candidates for multiple therapeutic applications.
Jill Steier, 212-213-0006
View original content to download multimedia:http://www.prnewswire.com/news-releases/siteone-therapeutics-appoints-scott-braunstein-md-to-board-of-directors-300710696.html
SOURCE SiteOne Therapeutics